To this concern, the treatment setting of front-line pembrolizumab in our country (NSCLC with PD-L1 ≥ 50%) does not include alternative treatment approaches according to regulatory approvals and, therefore, makes it impossible to settle on a proper control cohort to investigate the predictive value of identified prognostic factors. Here, CD274 is linked to non-small cell lung carcinoma.